1. Home
  2. TMCI vs KLRS Comparison

TMCI vs KLRS Comparison

Compare TMCI & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Treace Medical Concepts Inc.

TMCI

Treace Medical Concepts Inc.

HOLD

Current Price

$4.21

Market Cap

120.4M

Sector

Health Care

ML Signal

HOLD

Logo Kalaris Therapeutics Inc.

KLRS

Kalaris Therapeutics Inc.

HOLD

Current Price

$4.05

Market Cap

113.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TMCI
KLRS
Founded
2014
2019
Country
United States
United States
Employees
N/A
20
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
120.4M
113.0M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
TMCI
KLRS
Price
$4.21
$4.05
Analyst Decision
Hold
Strong Buy
Analyst Count
6
4
Target Price
$4.77
$19.00
AVG Volume (30 Days)
1.1M
63.9K
Earning Date
05-08-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$212,690,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$8.18
N/A
P/E Ratio
N/A
N/A
Revenue Growth
1.59
N/A
52 Week Low
$1.17
$2.14
52 Week High
$7.78
$11.88

Technical Indicators

Market Signals
Indicator
TMCI
KLRS
Relative Strength Index (RSI) 51.65 37.66
Support Level $3.84 N/A
Resistance Level $4.62 $4.86
Average True Range (ATR) 0.34 0.49
MACD -0.07 -0.04
Stochastic Oscillator 33.33 15.81

Price Performance

Historical Comparison
TMCI
KLRS

About TMCI Treace Medical Concepts Inc.

Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The Company operates and manages its business as one segment, which is the business of designing, manufacturing, and marketing medical devices for physicians, surgeons, ambulatory surgery centers and hospitals.

About KLRS Kalaris Therapeutics Inc.

Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.

Share on Social Networks: